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Regulatory B cells have largely been reported as B cells at a developmental stage before plasma cell differ-
entiation. Matsumoto et al. (2014) report that IL-10+ plasmablasts restrain autoimmune inflammation and
suggest an ontological connection between immature B cells and regulatory plasmablasts.The phenotypic identity of regulatory B
(Breg) cells that express the immunoregu-
latory cytokine interleukin-10 (IL-10) con-
tinues to be a matter of debate within
the field. A number of overlapping pheno-
types are currently used to describe these
cells. In mice, CD5+CD1dhi B10 B cells,
CD21hiCD23hiCD24hi transitional type 2
marginal zone precursors (T2-MZP) Breg
cells, and TIM-1+ B cells are all ascribed
regulatory function in a variety of autoim-
mune, infection, and transplantation set-
tings (Ding et al., 2011; Kalampokis
et al., 2013; Rosser et al., 2014). Although
it has been suggested that T2-MZP Breg
cells might be the precursors to B10
Breg cells, the relation of these subsets
to each other, and to TIM-1+ Breg cells,
has not been studied with any rigor (Ka-
lampokis et al., 2013). A more detailed
picture of the ontology of Breg cells and
their development throughout an immune
or autoimmune response is critical
missing information needed before their
existence can be exploited for hypothe-
sized therapeutic use in restoring immune
tolerance.
One common feature of the above Breg
cell subsets is that they are thought to be
primarily Pax5+ splenic B cells at a stage
of development prior to their terminal dif-
ferentiation into plasma cells (Mauri and
Bosma, 2012). In 2012, Maseda et al.(2012) first suggested that splenic Pax5+
B10Bcells could rapidly convert into plas-
mablasts after in vivo or in vitro activation,
though they did not test the regulatory ca-
pacity of the ‘‘daughter’’ plasmablasts.
However, Shen et al. (2014) reported that
IL-10- and IL-35-expressing Breg cells
were predominantly found within the
CD138+ plasma cell pool in experimental
autoimmune encephalitis (EAE) and mu-
rine Salmonella infection. In this issue of
Immunity, Matsumoto et al. (2014) extend
these results and show that endogenous
IL-10+ plasmablasts in the draining lymph
nodes (dLNs) of mice with EAE are
important for controlling autoimmune
inflammation and that they achieve this
by inhibiting dendritic cell activation. The
authors demonstrate that mice whose B
cells are deficient in genes that control
plasma cells differentiation, Irf4 and
Prdm1, develop more severe disease
than control mice.Moreover, they demon-
strate that Irf4 transcription is important
for the promotion of Breg cell Il-10 tran-
scription because IRF4 binds to a pro-
moter region of the Il-10 gene.
The most striking finding in the paper is
the lack of a need for splenic B cells for
Breg cell function in this model, because
plasmablast Breg cells develop and ac-
quire their function in dLNs. It has previ-
ously been suggested that the site ofmost efficient Breg cell recovery might
not always be the spleen. For instance,
in a Gnai2/ model of colitis where mice
are deficient for the G protein ai2 subunit,
the Breg cells most able to control colitis
were found in themesenteric lymph nodes
(MLNs) (Wei et al., 2005). Matsumoto et al.
(2014) examined the effects that splenec-
tomy or B-cell-specific CD62L deficiency,
a receptor that allows B cell entry to lymph
nodes, had on the development of EAE
and regulatory plasmablast generation.
Splenectomy did not affect the severity
of the disease or the generation of
CD138+CD44hi plasmablasts in the
dLNs. However, in mice lacking B cells
that expressed CD62L, plasmablasts
were undetectable in the dLNs and these
mice were unable to resolve EAE. Simi-
larly, adoptive transfer of Sell/ (encod-
ing CD62L) B cells to B-cell-deficient
mice was unable to inhibit EAE in the
same way as transfer of wild-type B cells.
In the absence of CD62L expression, B
cells could not enter the dLN and no regu-
latory plasmablasts were generated.
The redundancy of the spleen as a site
of Breg cell activity here is in marked
contrast to most Breg cell reports (Kalam-
pokis et al., 2013; Mauri and Bosma,
2012). In particular, transfer of splenic
B10 Breg cells has been reported to sup-
press EAE (Kalampokis et al., 2013). The
Figure 1. Hypothetical Breg Cell Development Pathways
IL-10+ T2-MZP or B10 Breg cells have been suggested to develop from the immature B cell pool in the spleen after CD40 and TLR stimulation. The data in
Matsumoto et al. (2014) allows the hypothesis that, with additional IFN-a and TLR9 stimulation, these cells can further develop to become regulatory plasmablasts
after recirculation to lymph nodes, or even directly in the spleen. Alternatively, regulatory plasmablasts might develop from mature B cells in the lymph nodes
during inflammation without the need for a regulatory B cell precursor. The final fate of regulatory plasmablasts is unclear and they might become long-lived
plasma cells.
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Previewsauthors suggest that the protective effect
of splenic B10 B cell transfer could be the
result of the migration of B10 B cells to
dLNs and their subsequent differentiation
into plasmablasts. To investigate this pos-
sibility, it would be helpful to determine
whether B10 B cells that lack the genes
necessary to develop into plasma cells,
Irf4 or Prdm1, could still inhibit EAE devel-
opment, and whether transferred B10
could be detected in the dLN. It is
currently assumed that B10 Breg cells
have regulatory activity at a stage before
they develop into antibody-secreting
cells; however, given the findings of Mat-
sumoto et al. (2014), it is possible they
achieve their full regulatory potential only
after differentiating into plasmablasts.
In addition to raising questions about
the development of murine B10 Breg
cells, Matsumoto et al. (2014) report
some initial findings with human B cells
that again suggest a developmental link
between a previously reported human
Breg cell subset and IL-10+ plasmablasts.
In healthy individuals, B cells with an
immature-like CD24hiCD38hi phenotype
have been described to possess the IL-
10-mediated ability to suppress T cell in-
flammatory cytokine production (Blair
et al., 2010). Matsumoto et al. (2014)
investigate what happens to immature,
naive mature, and memory B cells
after in vitro stimulation with com-
binations of CpG, IL-2, IL-6, and IFN-a.The authors show that these four
stimuli used all together induce naive
immature B cells to develop into IL-10-ex-
pressing CD27intCD38+ plasmablast-like
cells. Further, there is more IL-10 expres-
sion by plasmablast-like cells that
develop from immature naive B cells
than by plasmablasts that develop from
mature or memory B cells. Matsumoto
et al. (2014) did not, however, test the
suppressive function of the CpG-, IL-2-,
IL-6-, and IFN-a-induced human plasma-
blasts beyond IL-10 expression. Given
that the previous report on human imma-
ture-like Breg cells used different stimuli
to induce regulatory B cell function
(CD40 stimulation), further investigations
will be necessary to determine whether
these CD24hiCD38hi Breg cells are in
fact the precursors for a human plasma-
blast-like Breg cell.
Another outstanding issue from this
article is whether all plasmablasts act as
Breg cells or whether this function is ex-
erted by a particular subset. In character-
izing the plasmablasts that are generated
in the dLN during EAE, the authors show a
mixed phenotype in terms IgM and IgG
expression, with a reasonable degree of
class switching. However, the authors
do not costain for IL-10 and thus it is not
clear whether it is the IgM+ or the IgG+ pla-
mablasts that express more IL-10. The
authors report that disruption of Bcl6, a
gene that controls germinal center B cellImmunity 41, Dformation, does not significantly reduce
CD138+CD44hi plasmablast numbers,
nor does it exacerbate EAE development,
suggesting no loss of regulatory plasma-
blast function in these mice. Dent et al.
(1997) have previously reported that
Bcl6/mice have severely reduced class
switching in response to T-cell-dependent
antigens (such as those used to induce
EAE), with the majority of remaining
plasma cells secreting IgM. Similarly, in
humans, Matsumoto et al. (2014) found
that the stimuli used to induce IL-10+ plas-
mablasts also induced IgM secretion
(secretion of other isotypes was not
tested). Therefore, it seems plausible to
hypothesize that regulatory plasmablasts
are contained within the IgM+ plasmablast
pool of B cells. Both B10 and T2-MZP
Breg cells in mice, and CD24hiCD38hi
Breg cells in humans, express high levels
of IgM and could be the direct precursors
of theseregulatoryplasmablasts (Figure1).
However, it cannot be excluded that
during a humoral immune response, regu-
latory plasmablasts could differentiate
from the initial burst of short-lived IgM+
plasmablasts rather than from the soma-
tically hypermutated, class-switched,
long-lived plasma cells that develop later
(Figure 1). It would be interesting to
examine the degree of somatic hypermu-
tation in the IL-10+ plasmablast population
and the extent to which these cells persist
after the resolution of inflammation.ecember 18, 2014 ª2014 Elsevier Inc. 879
Immunity
PreviewsDo the regulatory plasmablasts
described here match those previously
described by Shen et al. (2014)? Pheno-
typically, there are a number of similarities
between the regulatory plasmablasts of
Matsumoto et al. (2014) and Shen et al.
(2014); both groups described them as
CD138+CD44hiCXCR4+ and possibly ex-
pressing IgM. However, a discrepancy
exists in their mechanism of action. Shen
et al. (2014) report a role for IL-35 produc-
tion by regulatory plasmablasts whereas
Matsumoto et al. (2014) could not detect
IL-35 expression, either directly ex vivo
or after brief PMA and ionomycin stimula-
tion in vitro. The difference is difficult to
reconcile because both groups used the
same model of EAE and both isolated
their cells at day 14 after EAE induction.
The difference might reflect the fact that
Shen et al. (2014) focus on splenic
CD138+ plasma cells, whereas Matsu-
moto et al. (2014) focus on CD138+CD44hi
plasmablasts in the dLN. Perhaps then
the IL-35+ regulatory plasma cells act
centrally and only IL-10+ regulatory880 Immunity 41, December 18, 2014 ª2014plasma cells are found in inflamed lymph
nodes.
In conclusion, Matsumoto et al. (2014)
have provided new evidence suggesting
that Pax5+ Breg cells can differentiate
into plasmablast Breg cells that up-
regulate IL-10 production as a result of
IRF4 transcription. These findings rein-
force the note of caution needed when
designing new B cell and/or plasma-
cell-directed therapies for the treatment
of patients with autoimmune diseases
or transplant recipients. Indiscriminate
elimination of all plasmablast cells might
lead to unexpected results due to the
depletion of regulatory plasmablasts
as well as autoreactive B cells and/or
plasmablasts.REFERENCES
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Although interleukin-17A (IL-17A) facilitates colon cancer development, its target cells remain elusive. In this
issue of Immunity, Wang et al. (2014) now demonstrate that IL-17A receptors on the intestinal epithelium
promote progression of APC mutant adenomas associated with IL-6 expression and that IL-17A confers
chemotherapy resistance.The interleukin-17 (IL-17) family of cyto-
kines is widely recognized for its ability
to modulate inflammatory responses.
Among the six IL-17 family members,
IL-17A and IL-17F are best understood
within lymphocyte populations. IL-17A
and IL-17F share similar expression
patterns and bind as ligand homo- or het-
erodimers to dimeric IL-17RA-IL-17RC re-
ceptor complexes to induce host defense
responses against bacterial pathogensat epithelial and mucosal barriers of the
skin, lung, and the colon (Gaffen, 2009).
In this issue of Immunity, Wang et al.
(2014) describe a mechanism by which
epithelial IL-17RA expression enables the
IL-17A-dependent progression of colon
tumors via IL-6 signaling, and they identify
IL-17A expression as a potential mecha-
nism of resistance to chemotherapy.
IL-17 cytokines are produced primarily
by mucosal lymphocytes, including natu-ral killer (NK) cells, CD4+ T helper 17
(Th17) cells, gd Tcells, and innate lym-
phoid cells (ILC), and by some nonhemo-
poietic cells, including the Paneth cells
of the small intestine. For the majority of
lymphocytes, IL-17 expression is contin-
gent on the transcription factors STAT3
and RORgt and the concerted activities
of IL-6 and transforming growth factor-b
(TGFb), and the phenotype of IL-17A
producing Th17 and ILC3 cells is
